Table 2.

Tozasertib-induced cytokinesis defects and necroptosis inhibition are not correlated

Inhibitor	Target	Cytokinesis		Necroptosis
		EC50	95% CI for EC50	IC50	95% CI for IC50
Nec-1s	RIPK1	NC	NC	0.367	0.187–0.739
Tozasertib	pan-Aurora	0.591	0.230–1.581	1.143	1.405–7.749
AMG-900	pan-Aurora	0.018	0.006–0.093	NC	NC
Barasertib	Aurora B	1.264	0.444–3.181	NC	NC
Danusertib	pan-Aurora	2.528	1.143–4.223	13.92	6.088–47.84
SNS-314	pan-Aurora	0.073	0.018–0.320	0.399	0.129–1.424

L929sAhFas cells were pre-treated with the indicated Aurora inhibitors (dose-response from 10 µM–0.0022 µM) for 1 h, followed by stimulation with mTNF (20 ng/mL) for 5 h. EC50 and IC50 values (µM) were calculated for, respectively, nuclear area and inhibition of necroptosis using nonlinear regression in GraphPad Prism 7. The 95% confidence intervals (CI) for IC50s are also indicated

NC not calculable